Network pharmacology, gut microbiota, and metabolomics integration reveal that Shenshuai 'an enema prescription (SSAEP) improves CRF mechanisms by reshaping the gut microbiota and correcting host–microbe cometabolism

BACKGROUND: Chronic renal failure (CRF) is a global health issue, and the "gut-kidney axis" plays a key role in its pathogenesis. Shenshuai 'an enema prescription (SSAEP) is a Chinese medicine compound based on the TCM theory of "regulation of bowel movement and removal of turbid qi", which has shown good adjunctive therapeutic effects in delaying the progression of CRF in clinical practice. However, its specific mechanisms remain unclear. PURPOSE: Herein, from the perspective of indirect pharmacology, the therapeutic effects of SSAEP on CRF rats were explored. We hypothesize that its mechanism of action may be largely indirect and occurs primarily through the gut-kidney axis. This study aimed to systematically elucidate the potential mechanism through which SSAEP improves CRF through the regulation of gut microecology using multidisciplinary approaches such as network pharmacology, 16S rRNA gene sequencing, and metabonomics. METHODS: A CRF rat model was established by induction with 2.5% adenine. Low and high doses of SSAEP were administered via enema, and antibiotic intervention and fecal microbiota transplantation (FMT) experiments were performed to verify the key mediating role of the gut microbiota. The chemical composition of the SSAEP and the metabolic profiles of the serum and colonic contents of the rats were analyzed using UHPLC‒MS/MS; the composition of the gut microbiota was analyzed through 16S rRNA sequencing; and the core targets and pathways were predicted using network pharmacology and molecular docking. In vitro, human renal tubular epithelial cells (HK-2) were stimulated with TGF-β1 or glycochenodeoxycholic acid (GCDCA) to verify the anti-inflammatory and antifibrotic effects of quercetin (the main active component of SSAEP) and the role of the IL-17 signaling pathway in this process. RESULTS: SSAEP treatment significantly improved renal function indicators (BUN, SCR, Cys-C, and UA) in CRF rats and alleviated pathological damage, the inflammatory response, and fibrosis in kidney tissue. Antibiotic intervention attenuated the protective effect of SSAEP, while FMT experiments confirmed that the efficacy of SSAEP could be transferred to recipient rats through the transplantation of treated fecal microbiota. SSAEP reshaped the gut microbiota, significantly increasing the abundance of Akkermansia while reducing that of Clostridium. Metabolomic analysis revealed CRF-related metabolic disturbances and identified 29 key differentially expressed metabolites regulated by SSAEP, among which glycochenodeoxycholic acid (GCDCA) was a key pathogenic metabolite. Network pharmacology predictions combined with in vitro experiments confirmed that the quercetin in SSAEP could effectively antagonize the TGF-β1- and GCDCA-induced epithelial‒mesenchymal transition and inflammatory response in HK-2 cells by inhibiting the IL-17/NF-κB signaling pathway. CONCLUSIONS: This study revealed that SSAEP improves CRF through an indirect pharmacological mechanism dependent on the gut microbiota: SSAEP reshapes the balance of the gut microbiota, thereby correcting host-microbe cometabolic disorders (particularly by reducing the level of the pathogenic metabolite GCDCA) and ultimately alleviating renal inflammation and fibrosis through the inhibition of signaling pathways such as the IL-17/NF-κB pathway. This study provides new experimental evidence for the "gut-kidney axis" theory and lays the foundation for the development of CRF treatment strategies based on the regulation of the gut microbiome.

Authors

Institutions

Publication Details

Journal
Chinese Medicine
Published
2026-11-13
DOI
https://doi.org/10.1186/s13020-026-01484-z
Primary Topic
Gut microbiota and health
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Network pharmacology, gut microbiota, and metabolomics integration reveal that Shenshuai 'an enema prescription (SSAEP) improves CRF mechanisms by reshaping the gut microbiota and correcting host–microbe cometabolism

Ye Qiu, Qiang Chen, Shilin Liu, Zheng Nan et al.
5 links
Chinese Medicine
Gut microbiota and health
article

Network pharmacology, gut microbiota, and metabolomics integration reveal that Shenshuai 'an enema prescription (SSAEP) improves CRF mechanisms by reshaping the gut microbiota and correcting host–microbe cometabolism

Ye Qiu, Qiang Chen, Shilin Liu, Zheng Nan, Andong Li, Zhidong Qiu, Ailing Jia
article en

Abstract

BACKGROUND: Chronic renal failure (CRF) is a global health issue, and the "gut-kidney axis" plays a key role in its pathogenesis. Shenshuai 'an enema prescription (SSAEP) is a Chinese medicine compound based on the TCM theory of "regulation of bowel movement and removal of turbid qi", which has shown good adjunctive therapeutic effects in delaying the progression of CRF in clinical practice. However, its specific mechanisms remain unclear. PURPOSE: Herein, from the perspective of indirect pharmacology, the therapeutic effects of SSAEP on CRF rats were explored. We hypothesize that its mechanism of action may be largely indirect and occurs primarily through the gut-kidney axis. This study aimed to systematically elucidate the potential mechanism through which SSAEP improves CRF through the regulation of gut microecology using multidisciplinary approaches such as network pharmacology, 16S rRNA gene sequencing, and metabonomics. METHODS: A CRF rat model was established by induction with 2.5% adenine. Low and high doses of SSAEP were administered via enema, and antibiotic intervention and fecal microbiota transplantation (FMT) experiments were performed to verify the key mediating role of the gut microbiota. The chemical composition of the SSAEP and the metabolic profiles of the serum and colonic contents of the rats were analyzed using UHPLC‒MS/MS; the composition of the gut microbiota was analyzed through 16S rRNA sequencing; and the core targets and pathways were predicted using network pharmacology and molecular docking. In vitro, human renal tubular epithelial cells (HK-2) were stimulated with TGF-β1 or glycochenodeoxycholic acid (GCDCA) to verify the anti-inflammatory and antifibrotic effects of quercetin (the main active component of SSAEP) and the role of the IL-17 signaling pathway in this process. RESULTS: SSAEP treatment significantly improved renal function indicators (BUN, SCR, Cys-C, and UA) in CRF rats and alleviated pathological damage, the inflammatory response, and fibrosis in kidney tissue. Antibiotic intervention attenuated the protective effect of SSAEP, while FMT experiments confirmed that the efficacy of SSAEP could be transferred to recipient rats through the transplantation of treated fecal microbiota. SSAEP reshaped the gut microbiota, significantly increasing the abundance of Akkermansia while reducing that of Clostridium. Metabolomic analysis revealed CRF-related metabolic disturbances and identified 29 key differentially expressed metabolites regulated by SSAEP, among which glycochenodeoxycholic acid (GCDCA) was a key pathogenic metabolite. Network pharmacology predictions combined with in vitro experiments confirmed that the quercetin in SSAEP could effectively antagonize the TGF-β1- and GCDCA-induced epithelial‒mesenchymal transition and inflammatory response in HK-2 cells by inhibiting the IL-17/NF-κB signaling pathway. CONCLUSIONS: This study revealed that SSAEP improves CRF through an indirect pharmacological mechanism dependent on the gut microbiota: SSAEP reshapes the balance of the gut microbiota, thereby correcting host-microbe cometabolic disorders (particularly by reducing the level of the pathogenic metabolite GCDCA) and ultimately alleviating renal inflammation and fibrosis through the inhibition of signaling pathways such as the IL-17/NF-κB pathway. This study provides new experimental evidence for the "gut-kidney axis" theory and lays the foundation for the development of CRF treatment strategies based on the regulation of the gut microbiome.

Chinese MedicineVol. 21(1)
Changchun University of Chinese Medicine (CN), The Affiliated Hospital to Changchun University of Chinese Medicine (CN)
People's Government of Jilin Province
Good health and well-being
Gut microbiota and health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon